{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:16:48Z","timestamp":1777918608637,"version":"3.51.4"},"reference-count":58,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The study aims to report the feasibility and safety of palliative hypofractionated radiotherapy targeting macroscopic bladder tumors in a monocentric cohort of frail and elderly bladder cancer patients not eligible for curative treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients who underwent hypofractionated radiotherapy to the gross disease or to the tumor bed after transurethral resection of bladder tumor from 2017 to 2021 at the European Institute of Oncology IRCCS, were retrospectively considered. Schedules of treatment were 30 and 25 Gy in 5 fractions (both every other day, and consecutive days). Treatment response was evaluated with radiological investigation and\/or cystoscopy. Toxicity assessment was carried out according to RTOG\/EORTC v2.0 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 16 patients were included in the study, of these 11 received hypofractionated radiotherapy on the macroscopic target volume and five on the tumor bed after transurethral resection of bladder tumor. No grade (G) &gt;2 acute toxicities were described after treatment for both groups. Only one patient in the group receiving radiotherapy on the macroscopic disease reported G4 GU late toxicity. Ten patients had available follow-up status (median FU time 18 months), of them six had complete response, one had stable disease, and three had progression of disease. The overall response rate and disease control rate were 60% and 70%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our preliminary data demonstrate that palliative hypofractionated radiotherapy for bladder cancer in a frail and elderly population is technically feasible, with an acceptable toxicity profile. These outcomes emphasize the potential of this approach in a non-radical setting and could help to provide more solid indications in this underrepresented setting of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916241252326","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:32:37Z","timestamp":1715319157000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?"],"prefix":"10.1177","volume":"110","author":[{"given":"Giulia","family":"Marvaso","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vitullo","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Corrao","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3149","authenticated-orcid":false,"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-4634","authenticated-orcid":false,"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Villa","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Kuncman","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Medical University of Lodz, Lodz, Poland"},{"name":"Department of External Beam Radiotherapy, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9990-694X","authenticated-orcid":false,"given":"Dario","family":"Zerini","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Repetti","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Lorubbio","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"},{"name":"Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"},{"name":"Division of Urology, IEO European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"bibr1-03008916241252326","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"bibr3-03008916241252326","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015"},{"key":"bibr4-03008916241252326","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (Version 1.2023), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder_blocks.pdf (accessed 16 April 2023)."},{"key":"bibr5-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3"},{"key":"bibr6-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"bibr7-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13900"},{"key":"bibr8-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.09.008"},{"key":"bibr9-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.12.015"},{"key":"bibr10-03008916241252326","volume":"9","author":"Bharadwaj M","year":"2022","journal-title":"Urol Oncol"},{"key":"bibr11-03008916241252326","doi-asserted-by":"crossref","unstructured":"Zlotta AR. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. 2023; 24(6): 669-681.","DOI":"10.1016\/S1470-2045(23)00170-5"},{"key":"bibr12-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.10.002"},{"key":"bibr13-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.028"},{"key":"bibr14-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7306198"},{"key":"bibr15-03008916241252326","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7453"},{"key":"bibr16-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.12.007"},{"key":"bibr17-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2101381"},{"key":"bibr18-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043266"},{"key":"bibr19-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1880025"},{"key":"bibr20-03008916241252326","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2019.11.02"},{"key":"bibr21-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01455-4"},{"key":"bibr22-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09593"},{"key":"bibr23-03008916241252326","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2018_180522N333"},{"key":"bibr24-03008916241252326","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102373"},{"key":"bibr25-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"bibr26-03008916241252326","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S361495"},{"key":"bibr27-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2008.04.001"},{"key":"bibr28-03008916241252326","first-page":"12","volume":"2017","author":"Folkert MR","journal-title":"Adv Drug Deliv Rev"},{"key":"bibr29-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.054"},{"key":"bibr30-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.05.071"},{"key":"bibr31-03008916241252326","doi-asserted-by":"crossref","unstructured":"Chen LN, Suy S, Uhm S, et al. Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Published online 2013:10.","DOI":"10.1186\/1748-717X-8-58"},{"key":"bibr32-03008916241252326","doi-asserted-by":"crossref","unstructured":"Alsadius D, Hedelin M, Lundstedt D, Pettersson N, WilderAng U, Steineck G. Mean Absorbed Dose to the Anal-Sphincter Region and Fecal Leakage among Irradiated Prostate Cancer Survivors. 2012;84(2):5.","DOI":"10.1016\/j.ijrobp.2012.03.065"},{"key":"bibr33-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00559-3"},{"key":"bibr34-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr35-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.05.002"},{"key":"bibr36-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14708"},{"key":"bibr37-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000350"},{"key":"bibr38-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.106"},{"key":"bibr39-03008916241252326","unstructured":"ESMO 2023: EV-302\/KEYNOTE-A39: Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma. Accessed January 4, 2024. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2023\/esmo-2023-bladder-cancer\/147538-esmo-2023-ev-302-keynote-a39-enfortumab-vedotin-in-combination-with-pembrolizumab-ev-p-vs-chemotherapy-in-previously-untreated-locally-advanced-metastatic-urothelial-carcinoma.html"},{"key":"bibr40-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"bibr41-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3116"},{"key":"bibr42-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.2541"},{"key":"bibr43-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00430-2"},{"issue":"2","key":"bibr44-03008916241252326","first-page":"407","volume":"18","author":"Zygogianni A","year":"2013","journal-title":"J BUON Off J Balk Union Oncol"},{"key":"bibr45-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2013.01.10"},{"key":"bibr46-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2013.06.06"},{"key":"bibr47-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-015-0999-8"},{"key":"bibr48-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2765-y"},{"key":"bibr49-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.01.239"},{"key":"bibr50-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-017-0318-3"},{"key":"bibr51-03008916241252326","doi-asserted-by":"publisher","DOI":"10.14440\/bladder.2018.785"},{"key":"bibr52-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.04.009"},{"key":"bibr53-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.068"},{"key":"bibr54-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-y"},{"key":"bibr55-03008916241252326","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.017"},{"issue":"3","key":"bibr56-03008916241252326","first-page":"940","volume":"26","author":"Stuk J","year":"2021","journal-title":"J BUON Off J Balk Union Oncol"},{"key":"bibr57-03008916241252326","author":"Bamias A","journal-title":"Eur Urol"},{"key":"bibr58-03008916241252326","unstructured":"Kang JJ, Iwamoto KS, Peek EM, Chin AC, King CR. The Low Alpha-Beta Ratio of Bladder Cancer: A Rationale for Hypofractionation. In: Proceedings of the 96th Annual Meeting of the American Radium Society 2014. Vol 28. Oncology Vol 28 No 4_Suppl_1. MJH Life Sciences; 2014. Accessed December 18, 2022. https:\/\/www.cancernetwork.com\/view\/s036-low-alpha-beta-ratio-bladder-cancer-rationale-hypofractionation"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916241252326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916241252326","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916241252326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:43:14Z","timestamp":1777660994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916241252326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/03008916241252326"],"URL":"https:\/\/doi.org\/10.1177\/03008916241252326","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}